New Study Shows Complex Financial Ties Between the Medical Product Industry and the Health Care Ecosystem

2022 ◽  
Vol 52 (2) ◽  
pp. 9-10
2020 ◽  
Vol 3 (2) ◽  
Author(s):  
Ridvan Yamanoglu

In the world market, medical products emerge as a sector that directly concerns people’s life quality and related activities. The medical product industry continues to grow rapidly in the world, especially in developed countries in line with the advances in technology, along with the elderly population and welfare level. In this context, biomedical implants constitute an important branch of the medical product industry. Among the materials preferred for implant production, the metallic biomaterials are very popular due to their superior mechanical properties. Ti and Ti alloys, among the metallic biomaterials, draw more attention considerably compared to stainless steel and Co-Cr alloys due to their characteristic features such as high specific strength and superior corrosion resistance, low density and low modulus of elasticity. Although the elastic modulus of titanium and its alloys is low compared to the other metallic biomaterials, it remains higher than bone. β-type Ti alloys have been developed to prevent the stress shielding effect caused by the elastic modulus mismatch and sterilization of the biomaterials used in the body from toxic alloy elements. In this article, the effect of the use of β-type Ti alloys, which are extremely prospective materials and open to development, in the body on host organisms, and the efficiency of the developed alloys have been investigated.


Author(s):  
C. P. Guimarães ◽  
R.M. Naveiro ◽  
J.E.A. Pereira

BMJ ◽  
2021 ◽  
pp. e066576
Author(s):  
Susan Chimonas ◽  
Maha Mamoor ◽  
Sophia A Zimbalist ◽  
Brooke Barrow ◽  
Peter B Bach ◽  
...  

Abstract Objective To identify all known ties between the medical product industry and the healthcare ecosystem. Design Scoping review. Methods From initial literature searches and expert input, a map was created to show the network of medical product industry ties across parties and activities in the healthcare ecosystem. Through a scoping review, the ties were then verified, cataloged, and characterized, with data abstracted on types of industry ties (financial, non-financial), applicable policies for conflict of interests, and publicly available data sources. Main outcome measures Presence and types of medical product industry ties to activities and parties, presence of policies for conflict of interests, and publicly available data. Results A map derived through synthesis of 538 articles from 37 countries shows an extensive network of medical product industry ties to activities and parties in the healthcare ecosystem. Key activities include research, healthcare education, guideline development, formulary selection, and clinical care. Parties include non-profit entities, the healthcare profession, the market supply chain, and government. The medical product industry has direct ties to all parties and some activities through multiple pathways; direct ties extend through interrelationships among parties and activities. The most frequently identified parties were within the healthcare profession, with individual professionals described in 422 (78%) of the included studies. More than half (303, 56%) of the publications documented medical product industry ties to research, with clinical care (156, 29%), health professional education (145, 27%), guideline development (33, 6%), and formulary selection (8, 1%) appearing less often. Policies for conflict of interests exist for some financial and a few non-financial ties; publicly available data sources seldom describe or quantify these ties. Conclusions An extensive network of medical product industry ties to activities and parties exists in the healthcare ecosystem. Policies for conflict of interests and publicly available data are lacking, suggesting that enhanced oversight and transparency are needed to protect patient care from commercial influence and to ensure public trust.


Author(s):  
Arushi Jain ◽  
Vishal Bhatnagar

Today, Big Data is being leveraged in many industries from criminal justice to health care to real estate with powerful outcomes. Organizations are using Big Data to predict the future in turn making them smarter and efficient. All the health care data such as discharge and transfer patient data maintained in Computer based Patient Records (CPR), Personal Health Information (PHI), and Electronic Health Records (EHR). The use of Big Data analytics is becoming increasingly popular at health care centres, in clinical research, and consumer based medical product development. The biggest challenge with implementation of big data is that the nature of information of public health sector is of very sensitive nature and needs to be protected from unauthorized access and release of contents. Therefore, to provide solution to the deidentifying personal health big data in this paper we author make use of only mapper job framework for data encryption.


2017 ◽  
Vol 7 (4) ◽  
pp. 72-86
Author(s):  
Arushi Jain ◽  
Vishal Bhatnagar

Today, Big Data is being leveraged in many industries from criminal justice to health care to real estate with powerful outcomes. Organizations are using Big Data to predict the future in turn making them smarter and efficient. All the health care data such as discharge and transfer patient data maintained in Computer based Patient Records (CPR), Personal Health Information (PHI), and Electronic Health Records (EHR). The use of Big Data analytics is becoming increasingly popular at health care centres, in clinical research, and consumer based medical product development. The biggest challenge with implementation of big data is that the nature of information of public health sector is of very sensitive nature and needs to be protected from unauthorized access and release of contents. Therefore, to provide solution to the deidentifying personal health big data in this paper we author make use of only mapper job framework for data encryption.


2020 ◽  
Vol 29 (4) ◽  
pp. 253-261 ◽  
Author(s):  
Karen K. Giuliano

In this presentation, I will share my unconventional journey, starting from my first job as a critical care staff nurse to my current role as tenure-track faculty at the University of Massachusetts Amherst, where I hold a joint position with the Institute for Applied Life Sciences and the College of Nursing. Throughout this journey, I have had many opportunities to participate in interdisciplinary clinical outcomes research and medical product development as a staff nurse, clinical nurse specialist, and project lead from the clinical, industry, and academic perspectives. While passionate about my central clinical research interests in technology innovation and its responsible use in critical and acute care, the foundation of my approach is dedicated to the values and lessons of my earliest experiences in critical care bedside nursing: supporting and preserving the dignity and humanity of person-centered patient care. Early in my career as a critical care nurse, I realized how vitally important a critical care nursing perspective could be in the design of technology for meeting the critical care needs of patients, nurses, and other professionals who provide this care. As the nation’s largest group of health care professionals, nurses use more products than any other health care professional, and thus nurses have a uniquely practical and care-sensitive perspective on the development and design of medical products. Nurses, especially critical care nurses, are in a unique position to identify and address everyday health care issues, challenge assumptions and the status quo, address unrecognized and unarticulated needs, and ensure that clinical outcomes research serves as the foundation for validating the effectiveness of medical product innovation. My goal is to share lessons learned and to help participants to see the many different ways that critical care nursing knowledge can be used to improve patient care


2018 ◽  
Vol 84 (19) ◽  
Author(s):  
Bahar Djouiai ◽  
Joanne E. Thwaite ◽  
Thomas R. Laws ◽  
Fabian M. Commichau ◽  
Barbara Setlow ◽  
...  

ABSTRACTThe high intrinsic decontamination resistance ofFirmicutesspores is important medically (disease) and commercially (food spoilage). Effective methods of spore eradication would be of considerable interest in the health care and medical product industries, particularly if the decontamination method effectively killed spores while remaining benign to both humans and sensitive equipment. Intense blue light at a ∼400 nm wavelength is one such treatment that has drawn significant interest. This work has determined the resistance of spores to blue light in an extensive panel ofBacillus subtilisstrains, including wild-type strains and mutants that (i) lack protective components such as the spore coat and its pigment(s) or the DNA protective α/β-type small, acid-soluble spore proteins (SASP); (ii) have an elevated spore core water content; or (iii) lack enzymes involved in DNA repair, including those for homologous recombination and nonhomologous end joining (HR and NHEJ), apurinic/apyrimidinic endonucleases, nucleotide and base excision repair (NER and BER), translesion synthesis (TLS) by Y-family DNA polymerases, and spore photoproduct (SP) removal by SP lyase (SPL). The most important factors in spore blue light resistance were determined to be spore coats/pigmentation, α/β-type SASP, NER, BER, TLS, and SP repair. A major conclusion from this work is that blue light kills spores by DNA damage, and the results in this work indicate at least some of the specific DNA damage. It appears that high-intensity blue light could be a significant addition to the agents used to kill bacterial spores in applied settings.IMPORTANCEEffective methods of spore inactivation would be of considerable interest in the health care and medical products industries, particularly if the decontamination method effectively killed spores while remaining benign to both humans and sensitive equipment. Intense blue light radiation is one such treatment that has drawn significant interest. In this work, all known spore-protective features, as well as universal and spore-specific DNA repair mechanisms, were tested in a systematic fashion for their contribution to the resistance of spores to blue light radiation.


Sign in / Sign up

Export Citation Format

Share Document